

Collaboration with Apellis

rare **strength**



October 27th, 2020



Forward looking statements

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum AB (publ), By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.



Guido Oelkers | CEO



Henrik Stenqvist | CFO



Ravi Rao | Head of R&D and CMO





Apellis

COLLABORATION WITH APELLIS
for global co-development and ex-US commercialisation rights
of systemic pegcetacoplan

Systemic pegcetacoplan supports all of Sobi's strategic priorities

Differentiated asset

- Differentiated asset with solid scientific basis
- Sales opportunity of up to USD 1 bn

Strategic fit with Sobi

- Strong strategic fit to our Haematology and Immunology therapeutic areas




Strengthen pipeline

- Boosts Sobi's late-stage pipeline from 7 to 12 at-scale projects

Catalyst for internationalisation

- Catalyst for international expansion, improves our sales potential in Russia, China and Japan by > 50 per cent


The collaboration is for systemic pegcetacoplan ex-US



Systemic pegcetacoplan in 5 indications

- **Haematology**
 - Paroxysmal nocturnal haemoglobinuria (PNH)
 - Cold agglutinin disease (CAD)
 - Haematopoietic stem cell transplantation-thrombotic microangiopathy (HSCT-TMA)
- **Nephrology**
 - Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G)
- **Neurology**
 - Amyotrophic lateral sclerosis (ALS)

New indications potentially expand Sobi's patient population in rare disease





Summary of the deal terms

<p>Upfront</p>	<ul style="list-style-type: none"> • USD 250 million
<p>R&D Payments</p>	<ul style="list-style-type: none"> • USD 80 million over four years to support the initial development plan (PNH, IC-MPGN/C3G and ALS, and new studies in CAD and HSCT-TMA)¹
<p>Milestones</p>	<ul style="list-style-type: none"> • Contingent milestones: Up to USD 915 million (in regulatory and commercial payments)
<p>Royalties</p>	<ul style="list-style-type: none"> • Tiered double-digit royalties on sales ranging from high teens to high twenties

¹ Further R&D to be agreed by both parties and split 50:50


Systemic pegcetacoplan has the potential to be the first targeted C3 therapy

Differentiation from approved C5 inhibitors



The systemic pegcetacoplan programme has multiple inflection points

Illustrative timeline for systemic pegcetacoplan programme




Systemic pegcetacoplan transforms Sobi's late-stage pipeline

Sobi late-stage product pipeline

■ Current pipeline of major development projects


■ Pipeline with Apellis partnership



Supports expanding international footprint

Systemic pegcetacoplan

- Sobi territory: Europe and Canada
- Sobi territory: other
- Sobi territory: China, Japan and Russia
- Apellis territory



Systemic pegcetacoplan...

...accelerates our Haematology business in the EU

...increases our commercial potential by > 50% in Russia, China and Japan

...will act as catalyst for further internationalisation

Systemic pegcetacoplan supports all of Sobi's strategic priorities



Differentiated asset

- Differentiated asset with solid scientific basis
- Sales opportunity of up to USD 1 bn

Strategic fit with Sobi



- Strong strategic fit to our Haematology and Immunology therapeutic areas



Strengthen pipeline

- Boosts Sobi's late-stage pipeline from 7 to 12 at-scale projects

Catalyst for internationalisation



- Catalyst for international expansion, improves our sales potential in Russia, China and Japan by > 50 per cent



